, and Genovefa Kolovou, MD, PhD 2 We thank Tzovaras et al for their letter 1 regarding our previous study linking gene polymorphisms of tumor protein p53 with left main coronary artery disease. 2 In their letter, the association between cardiovascular disease (CVD) and cancer is briefly discussed. 1 In this context, apart from p53 gene, there are other genes that may contribute to the progression of both atherosclerosis and cancer. For example, the paraoxonase (PON) gene family, including 3 proteins (PON1, PON2, and PON3), has been involved in the development of CVD and cancer, thus representing potential therapeutic targets for these diseases. 3, 4 Similarly, lectin-like oxidized low-density lipoprotein (LDL) receptor 1 has been reported to contribute to tumorigenesis and atherogenesis; therefore, its gene variants may affect susceptibility/protection from cancer and CVD. 5 C-reactive protein, a well-established marker of inflammation and atherosclerosis, 6-8 may also predict cancer prevalence and outcomes. 9, 10 Lipoprotein lipase and cytochrome P450 CYP1A1 are also implicated in tumor progression and/or prevention, 11, 12 apart from their role in atherogenesis. 13, 14 These data highlight the presence of links between cancer and CVD in relation to several genes. Furthermore, modified LDL particles may act as codelivery polymers of anticancer therapy to tumor tissue. 15 Further large studies are needed to establish the clinical implications of such associations.
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